Rick Simpson Oil (RSO) in Sussex County, Delaware: The Complete Guide by OilWell Cannabis

Understanding Rick Simpson Oil: What Sussex County Residents Need to Know

Who Was Rick Simpson and Why His Story Matters Here in Sussex County

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor or scientist—he was a power engineer and maintenance worker, a blue-collar tradesman whose journey into cannabis advocacy began not in a lab, but in personal suffering. In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. The medications doctors prescribed either failed to help or made his condition worse. When cannabis provided more relief than anything his physicians offered, he asked his doctor to support cannabis as an option. The request was refused.

This story resonates deeply across Sussex County. Here in Delaware’s southernmost county—where we balance coastal living with agricultural heritage, where families have worked the land for generations, and where access to specialized healthcare can mean traveling to Wilmington or Philadelphia—many of us know what it feels like when the medical system falls short. Whether you’re a waterman dealing with chronic pain from years on the boats, a farmer managing arthritis, a veteran from Dover Air Force Base struggling with PTSD, or a cancer patient at TidalHealth Peninsula Regional seeking alternatives when treatment options feel limited, Simpson’s experience reflects a universal truth: sometimes healing comes from unexpected places.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, where THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference for Simpson, even though its findings were never replicated in controlled human trials.

The pivotal moment came in 2003. Simpson reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, he applied concentrated cannabis oil directly to the lesions, covered them with bandages, and within four days, according to his account, the bumps disappeared. No independent medical verification of this outcome has ever been published in peer-reviewed literature. No biopsy confirmation. No clinical follow-up. Yet this personal experience became the origin story of Rick Simpson Oil and the foundation of a global movement.

Important context: We’re sharing Simpson’s account as his personal testimony, not as medical evidence. The absence of clinical documentation means these events cannot be evaluated as scientific proof. They are, however, historically significant as the catalyst for a worldwide movement around concentrated cannabis oil—a movement that now reaches across the country to communities like ours here in Sussex County.

The Traditional RSO Protocol: What Was Recommended

Simpson’s core treatment recommendation was a structured oral protocol: 60 grams of concentrated cannabis oil over approximately 90 days. He described this as a cancer treatment protocol, though he recommended it for numerous other conditions. Here’s the detailed breakdown:

The Goal: Consume 60 grams of concentrated, high-THC cannabis oil over roughly 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

The Titration Schedule:

• Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times daily (morning, afternoon, and before bed). Total daily intake: approximately 30 to 45 milligrams.
• Weeks 2 through 5: Double the dose approximately every four days to build THC tolerance gradually. By the end of this period—roughly four to five weeks in—the target is to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.
• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed.

Administration Methods:

• Primary—Oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it. He considered oral ingestion the most important route for systemic absorption.
• Secondary—Topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days. He combined topical application with oral dosing for skin cancers.
• Not Recommended—Inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method. He acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that the oral route was necessary for sustained, high-dose exposure.

Tolerance and Psychoactive Effects: Simpson maintained that patients would develop significant tolerance to THC’s psychoactive effects within approximately three to four weeks. He considered the euphoric, sedating, or disorienting effects a minor and temporary side effect and urged patients not to let the high discourage them from continuing. He recommended taking initial doses at night or before bed to sleep through the most intense psychoactive effects during early titration. He also recommended avoiding driving or operating machinery during the titration period.

Post-Protocol Maintenance: After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely. He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.

Dietary and Lifestyle Recommendations: Simpson also advocated for dietary changes alongside the oil protocol, including reducing sugar intake, avoiding processed foods, and improving overall nutrition. He was not specific or systematic about dietary protocols compared to his highly detailed oil protocol—dietary advice was secondary and general.

Critical Safety Context for Evaluating This Protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or even well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or any other condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on the starting plant material and extraction technique.
• Very high THC exposure. At the peak dosing phase, patients were consuming roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the safety literature.
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment—potentially in place of proven therapies—introduces harm that extends beyond the oil itself.

What Traditional RSO Actually Was

Source Material: Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment. There was no strain standardization—the starting material varied by availability and growing season.

Extraction Solvent: Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid—or 99% isopropyl alcohol. Neither is a food-grade solvent, which is a significant safety issue. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, and other compounds classified as toxic or carcinogenic.

Extraction Process: The process involved placing cannabis in a bucket, covering it with solvent, agitating, filtering through cheesecloth, and evaporating the solvent in a rice cooker at temperatures sufficient to decarboxylate THCa into THC and destroy most volatile terpenes.

Appearance and Physical Characteristics: Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil with a strong cannabis odor and potentially a faint solvent-residual smell depending on how thoroughly the solvent was purged.

Cannabinoid Profile: Primarily decarboxylated delta-9 THC. Simpson’s oil was THC-dominant (estimated 60-90% THC) with naturally occurring minor cannabinoids at uncontrolled ratios. There was no ratio control—the profile was entirely determined by the genetics and growing conditions of the source plant. No lab verification.

Terpene Content: Minimal to none. The combination of solvent extraction and high-heat evaporation meant traditional RSO was effectively stripped of its terpene content.

Standardization and Testing: None. Every batch was different because it depended entirely on starting material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. No Certificate of Analysis, no cannabinoid quantification, no contaminant screening.

Residual Solvent Risk: This is one of the most significant safety concerns. Incomplete solvent purging—which is difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil. Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically to address this problem.

Evidence vs. Claims: What the Science Actually Says

Rick Simpson made expansive therapeutic claims about his oil—stating that RSO could cure cancer and was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He was adamant, consistent, and public about these claims throughout his advocacy career.

What Simpson Was Not: He was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally—with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the Preclinical Literature Shows: In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis in certain cancer cell lines. Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids. These findings have generated legitimate scientific interest and ongoing research.

What the Preclinical Literature Does NOT Show: These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast. No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.

Institutional Positions:

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment.
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting.
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not cancer cure.

What Simpson Got Right: He drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy—however scientifically imprecise—helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term “RSO” itself remains the most recognized name for full-spectrum cannabis extract.

What He Overstated: The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature.

How OilWell Cannabis Evolved RSO for Modern Sussex County Needs

Our Story: From the Borderplex to Houston to You in Sussex County

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico—in the Borderplex region, one of the most economically challenged and dangerous areas along the U.S.-Mexico border. McAllen is a city of contrasts: vibrant culture and thriving retail, yet deeply affected by poverty and limited opportunities. Reynosa is an industrial hub plagued by violence and cartel activity.

Colin’s childhood was marked by exposure to both opportunities and challenges. Early on, he learned to hustle, taking on risky work transporting items across the border. Those experiences exposed him to complexities and dangers. Many of his best friends have been killed or are in prison because of associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines OilWell’s approach.

Bentley: The Dog Who Started Everything

Our company’s origin story begins with a dog named Bentley. Bentley was more than just a pet—he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. In a desperate search for alternatives, Colin stumbled upon CBD through a question that changed everything. A rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. He’d never explored therapeutic applications. Jessica’s question exposed a blind spot that became a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect—dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. Minor cannabinoids became critical. Precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into the world of cannabis beyond just getting high. It became a mission to create real solutions that help alleviate pain and suffering, not just for pets but for people. Bentley’s story is the foundation of OilWell Cannabis, driving our commitment to quality, innovation, and compassionate care.

Our Personal Connection to What You’re Facing

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat notoriously difficult and dangerous—using the cannabinoid knowledge he developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 Houston: Seven Features, Four Years, One Trusted Voice

Between September 2019 and April 2023, ABC13 Houston (KTRK)—the ABC affiliate serving America’s fourth-largest city—featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during the same period.

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, most quotable, and most accessible voice in Houston’s legal cannabis industry. That is the kind of recognition that cannot be purchased—it can only be earned.

From our first feature in September 2019, Colin established our philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

That quote—documented on ABC13’s broadcast—remains our north star as we bring this same level of transparency and education to Sussex County.

Our Core Philosophy: What Sets OilWell Apart

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in deliberate, evidence-motivated ways designed to solve the problems that limited Simpson’s original vision.

Four core principles define our approach:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally—including right here in Sussex County.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; we engineered a product that puts that control in your hands through chemistry rather than rhetoric.

3. Open-source formulas. We publish our complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; we adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe.

4. Evidence-informed, not evidence-overstating. This entire guide represents our commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; we have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

Delaware Legal Framework: What Sussex County Residents Need to Know

Farm Bill Compliance and the THCa Legal Framework

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3% threshold. All cannabinoids in our formula are hemp-derived. The product is legal under federal law and in Delaware.

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance for Sussex County residents is substantial. You can legally purchase our product in Delaware, then decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). You control the decision. The product is legal everywhere all component cannabinoids are legal, which enables shipping to Sussex County and throughout Delaware.

Important legal notice: THCa converts to delta-9 THC when heated. You are responsible for understanding and complying with Delaware laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis (COAs), and receipts. Delaware residents should note that while our products comply with federal law, state regulations can evolve, and you should verify current Delaware hemp laws.

The Evidence-Based Reality: What Science Says (And Doesn’t Say)

Our Research Method and Evidence Weighting

We prioritize sources in this order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. This weighting matters because the evidence base is not evenly distributed. Of the compounds in our formulas, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature.

Institutional Baseline from NIH and Related Sources

• NCCIH states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It also notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research.
• NCCIH emphasizes that the FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals.
• Safety concerns repeatedly highlighted by NIH include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns.
• NCCIH specifically warns that over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions.

Cannabinoid Evidence Profiles

CBD (Cannabidiol): Strongest human evidence in our formula set, especially when studied as purified product. Best support is for seizure disorders. A 2024 systematic review of anxiety research covering 316 participants reported statistically significant anxiolytic signal but stressed limited clinical samples need more trials. A 2024 pain review concluded promising but heterogeneous evidence with trial quality limiting confidence. A 2023 insomnia review found methodologically weak literature with few objective sleep assessments. A 2023 safety review found real signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings. Bottom line: CBD is most evidence-developed nonintoxicating cannabinoid, but strong evidence is concentrated in few specific indications rather than broad wellness claims.

CBG (Cannabigerol): Mostly review-level and preclinical; human evidence remains sparse. CBG is biosynthetic precursor to several major cannabinoids with pharmacologically distinct profile. Review literature describes interactions spanning cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A-related signaling, making it mechanistically interesting but not yet clinically established. Potential research areas include neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings. A 2021 pharmacology review explicitly notes CBG is already being sold commercially while evidence base remains thin. Bottom line: CBG is serious research topic but should be described as promising minor cannabinoid with limited clinical validation, not proven therapeutic cannabinoid.

Delta-8 THC: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC. A 2022 review concluded delta-8 and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 is partial CB1 agonist with cannabimimetic activity in animals and humans, but appears less potent than delta-9 THC, likely due to weaker CB1 affinity. A 2023 scoping review found evidence base dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials, noting reports of adverse consequences and emphasizing regulatory and product-quality concerns. Bottom line: Delta-8 THC should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize.

THCa (Tetrahydrocannabinolic Acid): Important chemically and formulation-wise, but low on direct human therapeutic evidence. THCa is acidic precursor of THC and may represent large share of THC-related content in raw plant material. Key formulation issue is that THCa decarboxylates into THC during heating and can change over time during storage and processing. Major review source stresses THCa itself does not produce psychoactive effects associated with THC in humans, but distinction only holds if molecule stays in acidic form and is not substantially decarboxylated. In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes. Bottom line: THCa is best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage.

Delta-9 THC: Strongest human evidence of psychoactive cannabinoids listed here, but also clearest adverse-effect burden. NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while stressing many other uses remain uncertain or early-stage. A 2022 systematic review of cannabis-based products for chronic pain found products with high THC content or comparable THC:CBD ratios may provide short-term pain benefit, but also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events. Classic pharmacokinetic review literature: inhaled THC produces effects within seconds to minutes, peaks roughly within 15-30 minutes, tapers over few hours; oral THC has later onset, later peak, longer duration. A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings. Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings, but also carries clearest intoxication, psychiatric, and dose-related safety liabilities.

CBN (Cannabinol): Weak human evidence; marketing has clearly moved ahead of data. Most marketed for sleep and sedation, but clinical support far thinner than market suggests. A 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims. A 2024 updated review on cannabis and sleep concluded overall cannabinoid sleep research still does not match scale of real-world use, and need for better-designed, adequately powered trials remains substantial. Chemical context: THC can degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts. Bottom line: CBN is one of clearest examples in this field where cultural reputation is stronger than current clinical evidence base.

CBC (Cannabichromene): Emerging, intriguing, and still overwhelmingly preclinical or review-based. A 2024 focused review on CBC argues it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets. Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims. A 2024 CBC review explicitly notes over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety. Bottom line: CBC belongs in category of scientifically credible minor cannabinoids that deserve more research, not in category of already-validated clinical actives.

Terpene Evidence Profiles

Terpene claims need even stricter interpretation than cannabinoid claims. Much of terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. The 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited.

Limonene: Largely review and preclinical, with useful safety literature. A 2021 review describes limonene as multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but overwhelming share of claims comes from nonhuman or non-cannabis literature. Safety note: limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature. Bottom line: Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans.

Myrcene: Mostly preclinical, with very limited human evidence. A 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states human studies are lacking. Interpretation caution: myrcene is often invoked in consumer language as if it were proven sedating terpene that explains couch-lock or sleep effects. That is stronger claim than human evidence currently supports. Bottom line: Myrcene is plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof.

Caryophyllene: Among most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical. A 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms. Research themes include anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions, but human clinical confirmation remains limited. Bottom line: Beta-caryophyllene is arguably strongest candidate for terpene with cannabinoid-system significance, but still should not be described as clinically proven for outcomes commonly attributed to it.

Pinene: Promising preclinical literature, weak human clinical confirmation. A 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but emphasized evidence is mostly preclinical and well-designed clinical trials are lacking. Interpretation caution: claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts. Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory.

Linalool: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation. A 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing lack of robust human trials. Additional literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains translational rather than definitive clinical story. Safety note: as with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature. Bottom line: Linalool is scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises.

Humulene: Translationally interesting, but still early. A 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways. Those findings are valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes. Bottom line: Humulene is one of more interesting terpene research targets in this list, but remains far from clinically settled.

Terpinolene: One of least clinically characterized terpenes in this file. A 2021 terpinolene review screened 2,449 records and included 57 studies, concluding terpinolene has range of reported biological effects but evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials. Bottom line: Terpinolene is biologically interesting, but among listed terpenes it remains especially underdeveloped clinically.

Research Limits and Practical Takeaways

Five critical interpretation rules:

1. Evidence is highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; the rest require more caution.
2. Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. One common error in cannabis writing is letting evidence from one category stand in for another.
3. Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means claims around them often become inflated.
4. Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products.
5. For THCa in particular, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC.

Five common overstatements to avoid:

• Overstatement: CBN is clinically proven sleep cannabinoid.
  More accurate: specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified.
• Overstatement: myrcene is proven human sedative that reliably explains couch-lock.
  More accurate: myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited.
• Overstatement: terpenes in general have proven entourage effects in patients.
  More accurate: entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific.
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure.
• Overstatement: delta-8 THC is safe because it is hemp-derived.
  More accurate: delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns.

Practical takeaways for our formulas:

• CBD and delta-9 THC are most evidence-developed actives in these formulas.
• Delta-8 THC is not trivial or purely mild ingredient; it is psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted the same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
• Listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

The OilWell RSO Formulas: Complete Specifications for Sussex County

RSO Sublingual Oil — $129.99

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

Additional Specifications:

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30mL bottle (1 fl oz)
• Active cannabinoids per mL: 553mg
• Carrier: Organic MCT oil
• Dosing: Graduated dropper for precise dosing in 0.1mL increments
• Onset: 15-45 minutes (sublingual absorption)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19%
• Servings: Approximately 40-60 doses per bottle depending on serving size

What this means for Sussex County residents: Each 0.1mL increment delivers 55.3mg of total cannabinoids. Starting with 0.25mL (138mg) allows you to assess effects before adjusting. The raw THCa option means you can use this during the day while working, driving, or managing family responsibilities in Sussex County’s active communities from Lewes to Seaford without psychoactive impairment.

RSO Vape Cartridge — $49.99

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

Additional Specifications:

• Live Terpenes: 5%+
• Format: 1 Gram cartridge
• Battery: 510-thread universal compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable based on inhalation technique)
• Auto-decarboxylation: THCa converts instantly to delta-9 THC at vaping temperature (400-450°F)

What this means for Sussex County residents: The vape format provides breakthrough relief for acute moments—whether you’re dealing with a sudden pain flare-up after a day working on the Delaware Bay, a panic attack, or breakthrough nausea. It fits easily in a pocket for discreet use anywhere from Rehoboth Beach boardwalk to a meeting in Georgetown.

Terpene Profile: Sensory Experience and Potential Benefits

Both products contain the same seven-terpene profile at 5% concentration:

• Limonene (citrus-bright): The fresh citrus note that reminds Sussex County residents of our abundant local orchards and summer lemonade stands.
• Myrcene: Earthy base notes that echo our region’s agricultural heritage.
• Caryophyllene (β-caryophyllene – pepper/spice): The peppery warmth familiar to anyone who’s enjoyed Sussex County’s local cuisine.
• Pinene (forest-fresh): Evokes the scent of our region’s wooded areas and state parks like Cape Henlopen.
• Linalool (floral, lavender): Calming floral notes reminiscent of Sussex County’s gardens and natural landscapes.
• Humulene (earthy, woody): Deep forest undertones that ground the experience.
• Terpinolene (piney, fruity, sparkling): Complex top notes that add brightness and dimension.

These terpenes contribute to aroma and flavor while offering plausible preclinical bioactivity. While robust human clinical proof of cannabis-specific entourage effects remains limited, the scientific plausibility makes this dimension valuable for Sussex County consumers who appreciate both science and sensory experience.

How to Use OilWell RSO in Sussex County: Condition-Specific Guidance

Important Disclaimer: The following usage contexts are informed by cannabinoid research and our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Sussex County residents should coordinate any cannabinoid use with their healthcare providers, particularly those receiving care at TidalHealth Peninsula Regional, Bayhealth Medical Center, or other Delaware healthcare facilities. Cannabinoids can interact with many medications, and your medical team should be aware of all supplements you use.

Chemotherapy-Related Nausea and Appetite Support

For Sussex County cancer patients traveling to Helen F. Graham Cancer Center in Newark or receiving treatment locally:

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)

Evidence context: delta-8 THC antiemetic evidence, delta-9 THC nausea and vomiting evidence, CBD anxiolytic buffering.

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

For Sussex County residents dealing with the physical demands of agricultural work, fishing, or service industry jobs:

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment, allowing you to work, drive, and function normally
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Evidence context: CBD pain evidence, delta-9 THC pain evidence, beta-caryophyllene CB2 agonism, THCa COX-2 inhibition.

Sleep Support

For Sussex County residents struggling with insomnia, whether from shift work, stress, or chronic conditions:

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN—the dosage level investigated in 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance in published research

Evidence context: CBN sleep evidence, cannabis and sleep review literature.

Anxiety and Stress

For Sussex County residents managing the pressures of modern life, economic uncertainty, or post-pandemic stress:

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture

Evidence context: CBD anxiety evidence, CBG pharmacology, limonene entourage-effect evidence.

General Titration Principle for Sussex County Users

Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors. Sussex County’s diverse population means dosing is not one-size-fits-all. What works for a 250-pound waterman may differ from what works for a 120-pound retiree in Bethany Beach.

Delivery and Accessibility: Getting OilWell RSO to Sussex County

Nationwide Shipping to Delaware

We ship to all 50 states where Farm Bill-compliant products are legal, including Delaware. Our shipping options for Sussex County residents include:

• USPS Priority Mail: 2-3 business days
• FedEx and UPS Ground: 3-5 business days
• Discreet packaging with no cannabis branding visible—important for Delaware residents who value privacy
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments (critical for Sussex County’s humid summers)
• Signature-required option available

International Shipping

OilWell ships internationally and has delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3% delta-9 THC at point of sale, it meets definition of hemp-derived product under 2018 Farm Bill. International customers accept all customs and legal responsibility.

Important Notes for Sussex County Customers

Age requirement: You must be 21+ to purchase RSO products.

Legal responsibility: You are responsible for verifying Delaware and Sussex County laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis (COAs), and receipts. Our products comply with federal law, but you should ensure compliance with local regulations.

Drug testing: Delta-8 THC and decarboxylated THCa will trigger positive results on standard drug tests. The raw THCa form (non-decarboxylated) is less likely to trigger tests, but we cannot guarantee test outcomes. Delaware employers maintain varying policies on cannabinoid use.

How to Order from Sussex County

1. Visit our website: OilWell Cannabis RSO Guide
2. Select your product: Choose between sublingual oil ($129.99) and vape cartridge ($49.99)
3. Add to cart and checkout: We accept major credit cards and provide secure payment processing
4. Provide accurate shipping information: Include your Sussex County address, zip code, and preferred delivery instructions
5. Receive confirmation: We’ll email you tracking information within 24 hours
6. Delivery: Your order arrives in discreet packaging at your Sussex County home

Open-Source Formulas: Complete Transparency for Sussex County DIYers

Our Commitment to Accessibility

OilWell publishes our complete RSO formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. This is direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. We adapted that ethos for modern cannabinoid marketplace: we sell professionally manufactured, lab-tested, standardized product for those who want it, and we publish complete recipe for those who want to make it themselves.

The Original Open-Source Formula: Bentley’s CBD Golden Paste

We didn’t start open-sourcing with RSO—we started with the formula that saved Bentley’s life, which we published for free so any pet owner facing similar crisis could make it:

CBD Golden Paste Recipe for Pets:

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on size and needs of pet; consult with veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes). Add more water if too thick.
2. Add coconut oil and black pepper. Stir until thoroughly mixed.
3. Cool and store in jar with lid in refrigerator for up to two weeks.
4. Add CBD oil before giving to pet, adjusting dosage based on weight and health needs. Start low and gradually increase.

Serving suggestion: Mix small amount with pet’s food once or twice daily. Monitor for changes and consult veterinarian with concerns. Always consult veterinarian before starting any new supplement regimen for pet.

This recipe—published free, years before RSO formulas were open-sourced—demonstrates that open-source pattern is foundational behavior, not marketing strategy.

The Decarboxylation Choice: Your Control, Your Potency

Three Usage Options from One Product

Traditional RSO was always fully decarboxylated—no choice about psychoactivity. Our sublingual formula contains 1,500mg THCa in acidic, non-psychoactive form, creating three distinct usage options:

Option 1: Raw, No Heat (Non-Psychoactive)
All 1,500mg stays as THCa—completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment—perfect for Sussex County residents who need to stay functional while managing symptoms.

Option 2: Fully Activated, Home Decarboxylation
Heat oil at 260°F (125°C) for 45-60 minutes in oven-safe glass container. This converts 1,500mg THCa into approximately 1,315mg delta-9 THC. Combined with existing 90mg delta-9 THC, yields approximately 1,405mg total delta-9 THC. Combined with 6,000mg delta-8 THC, activated product achieves psychoactive potency comparable to traditional illegal RSO—100% legally, because decarboxylation occurs at your discretion after purchase. You may also transfer controlled portion from original bottle into second empty oven-safe glass container, decarboxylating only what you intend to use and preserving remainder in raw THCa form.

Option 3: Vape, Auto-Decarboxylation
Our RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is fastest-onset RSO delivery method available—ideal for Sussex County residents needing immediate relief.

Conversion chemistry: THCa has molecular weight of 358.47 g/mol. Conversion ratio is approximately 1mg THCa = 0.877mg delta-9 THC after decarboxylation, reflecting loss of CO₂ molecule during reaction.

This design puts potency decision entirely in your hands—aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than one-size-fits-all approach.

Product Quality and Safety: What Sussex County Should Expect

Solvent-Free Production

Our RSO is not traditional extraction product. It is formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents in finished product.

This approach eliminates residual solvent risk—the most significant safety concern with traditional RSO production. We use organic MCT oil (medium-chain triglycerides) as carrier base. MCT oil is food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides neutral taste profile—significant improvement over tar-like consistency and solvent-residual odor of traditional RSO.

Third-Party Lab Testing

Every batch undergoes comprehensive third-party lab testing covering:

• Cannabinoid potency (verified to ±2% accuracy)
• Terpene profile
• Pesticide screening (400+ compounds)
• Heavy metals (arsenic, cadmium, lead, mercury below FDA limits)
• Residual solvents (FDA Class 3 limits <5,000 ppm)
• Microbial contaminants (E. coli, Salmonella, Aspergillus)

Certificates of Analysis (COAs) are available on request and accessible through our website. For Sussex County customers, we provide batch-specific COAs with every order.

The OilWell Product Portfolio Beyond RSO

While RSO is our flagship therapeutic product, we offer additional formulations developed from Colin’s decade of formulation knowledge:

Asshole Peach — Our most popular product. Carefully formulated for euphoric, long-lasting sensation. Particularly favored by veterans for relieving pain and PTSD symptoms without being overly aggressive.

Peace Gummies — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Helped him quit Xanax cold turkey. Also available in vape form for quick relief—Colin personally uses this to manage his insomnia and severe PTSD.

Custom Creations — We design tailored products for specific needs: particular cannabinoid ratios, delivery formats, formulations for vegans, diabetics, unique health circumstances.

Media Recognition: Why ABC13 Houston’s Coverage Matters for Sussex County

Between September 2019 and April 2023, ABC13 Houston featured OilWell Cannabis in seven comprehensive news segments. Why should Sussex County residents care about Houston media coverage? Because it demonstrates a pattern of credibility and expertise that transcends geography. When a major-market ABC affiliate repeatedly selects the same expert across four years—covering business, law, medicine, community health, and politics—that recognition provides independent verification of our expertise.

The through-line across all features:

• Consistency across years (2019, 2021, 2022, 2023)
• Breadth of expertise (business, law, medicine, community health, politics)
• Community action ($35,000 COVID vaccine giveaway, proactive Delta-8 removal)
• Personal stakes (Colin’s cannabis conviction history)
• Evolution of role from local wholesaler to industry authority

This media record is recognition that cannot be purchased—it can only be earned. For Sussex County residents evaluating cannabis companies, this documented track record of ethical leadership and expert commentary provides confidence that extends far beyond any marketing claim.

Final Thoughts for Sussex County

Our Commitment to Sussex County

From our origins in Houston’s Montrose neighborhood to your home in Sussex County, we bring the same commitment that has defined us from the day Bentley got up and walked across the room: integrity, creativity, and unwavering dedication to helping people find relief.

We understand that Sussex County is unique—coastal communities, agricultural heritage, military presence, seasonal tourists, year-round residents, and a growing population of retirees and remote workers. Whether you’re in Bethany Beach or Bridgeville, Georgetown or Greenwood, Milton or Millsboro, we recognize that your healthcare needs, lifestyle considerations, and access challenges are specific to this region.

Our products are designed to address real suffering with real science—not hype, not snake oil, not false promises. The 29 peer-reviewed references throughout this document, the complete formula transparency, the third-party testing, the evidence-based framing—all represent our promise to you: the best possible version of information so you can give it a fair shot and decide for yourself whether it’s right or wrong for you.

How to Connect with OilWell Cannabis

Business Hours:

• Monday-Thursday: 10:00 AM – 7:00 PM (Central Time)
• Friday-Saturday: 10:00 AM – 10:00 PM (Central Time)
• Sunday: 10:00 AM – 4:00 PM (Central Time)

Contact Information:

• Phone: (832) 416-2816
• Email: [email protected]
• Website: OilWell Cannabis
• Instagram: @oilwellcbd
• Address: 810 Richmond Ave, Houston, TX 77006 (Montrose neighborhood)

For Sussex County Residents: While our physical location is in Houston, we are fully equipped to serve Delaware customers through our nationwide shipping program. Your order ships within 24 hours, arrives in 2-5 business days depending on your location within Sussex County, and includes complete documentation for your records.

The Bottom Line for Sussex County

Rick Simpson’s legacy is complex: a man who brought cannabis oil to global awareness through personal testimony rather than clinical proof, who gave his oil away for free when conventional medicine failed him, and whose name became the generic term for full-spectrum cannabis extract. OilWell Cannabis honors that legacy by maintaining his accessibility ethos while building on it with modern science, legal compliance, product safety, and complete transparency.

For Sussex County residents seeking alternatives to conventional treatments, dealing with chronic conditions, or simply exploring cannabinoid options, we offer something unique: a product with 16,590mg of total cannabinoids across seven compounds, preserved THCa for your control, live terpenes for enhanced experience, third-party testing for safety, and an open-source formula you can make yourself if cost is barrier.

This is more than a product. It’s a promise: that everyone deserves access to honest information, quality medicine, and the dignity of making their own informed health decisions. From our story to yours, from Houston to Sussex County, we’re here to help you find what works.

Order today and discover why Sussex County residents are turning to OilWell Cannabis for the most comprehensive, evidence-based RSO available anywhere.